Franklin Resources Inc. Sells 527,256 Shares of Genmab A/S (NASDAQ:GMAB)

Franklin Resources Inc. reduced its holdings in Genmab A/S (NASDAQ:GMABFree Report) by 94.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,351 shares of the company’s stock after selling 527,256 shares during the quarter. Franklin Resources Inc.’s holdings in Genmab A/S were worth $966,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of GMAB. Headlands Technologies LLC bought a new stake in shares of Genmab A/S in the third quarter worth about $27,000. Pinnacle Bancorp Inc. grew its holdings in shares of Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after buying an additional 638 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Genmab A/S during the third quarter worth about $37,000. Principal Securities Inc. bought a new position in shares of Genmab A/S during the fourth quarter worth about $77,000. Finally, Advisors Preferred LLC bought a new position in shares of Genmab A/S during the fourth quarter worth about $82,000. 7.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of research reports. Truist Financial increased their price objective on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Monday. Finally, BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and raised their price target for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $49.25.

Read Our Latest Stock Analysis on GMAB

Genmab A/S Stock Down 0.7 %

GMAB opened at $28.55 on Friday. Genmab A/S has a 12-month low of $26.32 and a 12-month high of $42.72. The stock has a market cap of $18.88 billion, a price-to-earnings ratio of 23.79, a PEG ratio of 1.04 and a beta of 0.99. The business has a 50 day moving average of $29.01 and a 200-day moving average of $29.72.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The company had revenue of $603.30 million during the quarter, compared to analysts’ expectations of $594.23 million. As a group, analysts expect that Genmab A/S will post 1.11 earnings per share for the current year.

Genmab A/S Company Profile

(Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABFree Report).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.